文献速递消化系统肿瘤

循环肿瘤DNA是非转移性II期和III期结直肠癌肿瘤复发的预后标志物:多中心前瞻性队列研究(ALGECOLS)

Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
PubMed 文献 · Eur J Cancer · 2021-10-30

该多中心前瞻性队列研究纳入184例II期或III期结直肠癌患者,术前及术后纵向检测血浆循环肿瘤DNA(ctDNA),随访3-4年。术前27.5%患者ctDNA阳性,阳性者复发率32.7% vs 阴性者11.6%(P=0.001);术前、术后即刻及术后早期(1-6个月)可检测到ctDNA者复发时间均显著缩短。术后早期后ctDNA仍为预后标志物,较影像学随访中位提前13.1周诊断复发。

要点

  • 术前ctDNA阳性者复发率32.7%,阴性者11.6%(P=0.001)。
  • 术前可检测ctDNA者复发时间显著缩短(校正HR=3.58,95%CI 1.71-7.47)。
  • 术后早期(1-6个月)ctDNA阳性者复发时间显著缩短(校正HR=5,95%CI 1.9-12.9)。

核心结论

  • 本前瞻性研究证实ctDNA是II期和III期结直肠癌术前复发的相关危险因素,也是术后微小残留病的标志物,可能较影像学技术提前数月预测复发。

研究设计与样本

  • 多中心前瞻性队列研究(ALGECOLS),纳入184例II期或III期结直肠癌患者。
  • 术前及术后采集血浆,随访3-4年期间每次访视时检测ctDNA。
  • 采用微滴式数字聚合酶链反应(droplet-based digital PCR)靶向突变和甲基化标志物,对临床结局设盲分析。
  • 多因素分析校正年龄、性别、分期和辅助化疗。

主要发现

  • 术前27.5%患者ctDNA检测阳性。
  • 可检测到ctDNA者复发率32.7%,未检测到ctDNA者复发率11.6%(P=0.001)。
  • 术前可检测ctDNA者复发时间显著缩短(校正HR=3.58,95%CI 1.71-7.47)。
  • 术后即刻可检测ctDNA者复发时间显著缩短(校正HR=3.22,95%CI 1.32-7.89)。
  • 术后早期随访(1-6个月)可检测ctDNA者复发时间显著缩短(校正HR=5,95%CI 1.9-12.9)。

关键数值与推荐

  • 术前ctDNA阳性率27.5%。
  • 术前ctDNA阳性者复发率32.7% vs 阴性者11.6%(P=0.001)。
  • 术前ctDNA阳性者复发时间校正HR=3.58(95%CI 1.71-7.47)。
  • 术后即刻ctDNA阳性者复发时间校正HR=3.22(95%CI 1.32-7.89)。
  • 术后早期(1-6个月)ctDNA阳性者复发时间校正HR=5(95%CI 1.9-12.9);该时期之后ctDNA仍为预后标志物,较影像学随访中位提前诊断复发13.1周(四分位距28周)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究启动时未描述共识性分析前条件,ctDNA阳性率可能被低估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In non-metastatic colorectal cancer (CRC), we evaluated prospectively the pertinence of longitudinal detection and quantification of circulating tumor DNA (ctDNA) as a prognostic marker of recurrence. METHOD: The presence of ctDNA was assessed from plasma collected before and after surgery for 184 patients classified as stage II or III and at each visit during 3-4 years of follow-up. The ctDNA analysis was performed by droplet-based digital polymerase chain reaction, targeting mutation and methylation markers, blindly from the clinical outcomes. Multivariate analyses were adjusted on age, gender, stage, and adjuvant chemotherapy. RESULTS: Before surgery, 27.5% of patients were positive for ctDNA detection. The rate of recurrence was 32.7% and 11.6% in patients with or without detectable ctDNA respectively (P = 0.001). Time to recurrence (TTR) was significantly shorter in patients with detectable ctDNA before (adjusted hazard ratio [HR] = 3.58, 95% confidence interval [CI] 1.71-7.47) or immediately after surgery (adjusted HR = 3.22, 95% CI 1.32-7.89). The TTR was significantly shorter in patients with detectable ctDNA during the early postoperative follow-up (1-6 months) (adjusted HR = 5, 95% CI 1.9-12.9). Beyond this period, ctDNA remained a prognostic marker with a median anticipated diagnosis of recurrence of 13.1 weeks (interquartile range 28 weeks) when compared to imaging follow-up. The rate of ctDNA+ might be underestimated knowing that consensus pre-analytical conditions were not described at initiation of the study. CONCLUSION: This prospective study confirms the relevance of ctDNA as a recurrence risk factor in stage II and III CRC before surgery and as a marker of minimal residual disease after surgery that may predict recurrence several months before imaging techniques.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Benhaim L, Bouché O, Normand C, et al. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). Eur J Cancer. 2021. PMID: 34731746. doi:10.1016/j.ejca.2021.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。